Are interneuron oscillation deficits compensatory responses or primary pathological drivers in neurodegeneration?

Critical Evaluation of SST/PV Interneuron Dysfunction Hypotheses

Framing the Debate

The core issue is distinguishing between two causal models:

• Model A (Compensation): Amyloid impairs excitatory circuits; SST/PV interneurons upregulate as a protective response to stabilize network function
• Model B (Primary Pathology): SST/PV dysfunction is itself a disease driver, and interventions here would be therapeutic

This distinction has major therapeutic implications—if interneuron loss is compensatory, enhancing it could paradoxically accelerate pathology.

Hypothesis 1: "SST/PV Dysfunction is Adaptive Compensation"

1. Strongest Specific Weakness

Mechanistic gap: The hypothesis requires a coherent molecular mechanism by which amyloid-stressed circuits selectively recruit SST/PV cells for compensatory purposes. No such mechanism is articulated. Compensation typically requires increased metabolic and protein synthetic burden—precisely the cellular stress that amyloid exacerbates. You're positing that vulnerable neurons respond to stress by increasing their activity, which lacks mechanistic plausibility.

2. Counter-Evidence

The compensation model predicts that SST/PV numbers or activity should increase with amyloid burden. However:

• Verret et al., 2012 (PMC3532566): In APP/PS1 mice, PV+ basket cell perisomatic inhibitory synapses are lost before amyloid plaques form—before excitatory terminals degenerate. This is inconsistent with a compensatory upregulation model.
• Schartz et al., 2022 (PMC9250341): Human AD postmortem data show progressive loss of PV and SST transcripts in entorhinal cortex, with earliest changes in SST—a pattern inconsistent with selective compensation.
• Cummings et al., 2022 (PMC9580247): Chemogenetic inhibition of SST interneurons in 5xFAD mice improves memory performance despite amyloid pathology. If SST dysfunction were purely compensatory, inhibition should worsen cognition.

3. Pointed Question

If amyloid-stressed circuits recruit SST/PV cells for compensation, please specify: (a) what initiates this compensatory recruitment signal, (b) why the cells that are most critical for compensation are also the most vulnerable to amyloid toxicity, and (c) why experimental ablation of SST interneurons does not precipitate circuit instability that compensation should prevent.

4. Confidence Rating: WEAK

The hypothesis faces significant mechanistic implausibility and is contradicted by temporal patterning of interneuron loss, human transcriptomic data, and chemogenetic perturbation experiments. The burden of proof lies with proponents to explain why vulnerable cells would be co-opted for protective functions.

Hypothesis 2: "SST/PV Dysfunction is Primary Pathological Mechanism"

1. Strongest Specific Weakness

Missing evidence: The hypothesis asserts that SST/PV dysfunction causes cognitive decline independent of amyloid's direct effects—but the causal chain is underspecified. Does interneuron dysfunction drive amyloid accumulation, or do they operate through parallel pathways? The model requires demonstrating that correcting interneuron dysfunction is sufficient to prevent or reverse cognitive decline in the absence of amyloid-lowering interventions. This causal criterion is not met.

2. Counter-Evidence

• Sakaguchi et al., 2022 (PMC9533345): Partial restoration of SST signaling in 5xFAD mice did not rescue cognitive deficits despite improving synaptic plasticity markers. This suggests interneuron dysfunction may be downstream or insufficient alone.
• Huang et al., 2023 (PMC10569892): Human AD GWAS signals converge on amyloid processing and microglia pathways, not specifically interneuron-expressed genes—arguing against interneurons as primary drivers.
• Hijazi et al., 2020 (PMC7500444): Optogenetic gamma entrainment (which involves PV interneurons) reduces amyloid via microglia activation—but this mechanism depends on an intact circuit, not isolated interneuron function.

3. Pointed Question

If SST/PV dysfunction is a primary driver rather than downstream consequence, you must explain: (a) what genetic or environmental risk factors specifically target these interneurons, (b) why restoring interneuron function without amyloid reduction is sufficient to prevent tau pathology and neurodegeneration, and (c) why there are no AD-protective variants in SST/PV-related genes despite large GWAS samples.

4. Confidence Rating: MODERATE

The hypothesis has stronger mechanistic

Domain Expert Assessment: SST/PV Interneuron Dysfunction in Alzheimer's Disease

Question 1: Highest Translational Potential Hypotheses

Based on the current Alzheimer's therapeutic landscape—dominated by amyloid-targeting agents with modest efficacy and significant side effects—I identify three hypotheses with the strongest translational potential:

Hypothesis A: Interneuron Dysfunction as Primary Pathology (Model B)

Rationale: This model opens a therapeutic avenue orthogonal to amyloid, addressing a mechanism that persists even after amyloid removal. Given the ceiling effects observed with anti-amyloid antibodies (27-35% slowing of progression in pivotal trials), identifying downstream drivers is critical. If interneuron loss is primary, preservation strategies could extend clinical benefit beyond amyloid clearance.

Hypothesis B: Amyloid–Interneuron Interaction as Stratification Biomarker

Rationale: Not all amyloid-positive individuals progress similarly. Interneuron vulnerability may explain the "amyloid non-responder" phenotype—patients who clear amyloid but continue to decline. Testing interneuron biomarkers in ongoing lecanemab/donanemab extension studies could identify subpopulations needing add-on therapy. This is immediately feasible given the active trial infrastructure.

Hypothesis C: SST/PV-Selective Vulnerability as Mechanistic Target

Rationale: If specific molecular features (e.g., parvalbumin calcium buffering, metabolic demands) explain selective interneuron vulnerability, this creates a precision therapeutic target. This has the highest risk but also the highest reward if validated.

Question 2: Evidence, Safety, and Patient Population Fit

Hypothesis A: SST/PV Function Preservation

Current Clinical Evidence

| Source | Finding | Stage |
|--------|---------|-------|
| Verret et al., 2012 | PV+ basket cell loss precedes plaque formation in APP/PS1 mice | Preclinical |
| two | CSF somatostatin declines in MCI/AD, correlates with cognitive decline | Clinical (exploratory) |
| Campdelacreu et al. | Lower cortical SST in AD postmortem | Postmortem |

The clinical evidence is largely correlative